Pharmacokinetics and bioequivalence of sunitinib and Sutent® in Chinese healthy subjects: an open-label, randomized, crossover study

• Published in: Frontiers in pharmacology 2023-11, Vol.14, p.1294688-1294688
• Main Authors: Wang, Yanli, Deng, Qiaohuan, Gao, Zhenyue, Liu, Guangwen, Su, Zhengjie, Zhao, Yicheng, Zhang, Lixiu, Yang, Haimiao
• Format: Article
• Language: English
• Subjects: bioequivalence; pharmacokinetics; renal cell carcinoma; safety; sunitinib
• ISSN: 1663-9812; 1663-9812
• DOI: 10.3389/fphar.2023.1294688

Purpose: The purpose of this study was to examine the pharmacokinetics (PK), bioequivalence and safety of generic sunitinib and its original product Sutent ® in healthy Chinese subjects through a phase-I clinical trial. Methods: The study selected two groups of 24 healthy Chinese subjects in a 1:1 ratio through random allocation. Each participant received either 12.5 mg of sunitinib or Sutent ® per cycle. A total of 15 different time points were employed for blood sample collection during each cycle. Furthermore, a comprehensive assessment of the drugs’ safety was consistently maintained throughout the trial. Results: The average adjusted geometric mean ratios (GMR) (90% CI) for the primary PK parameters C max , AUC 0-t and AUC 0-∞ were 97.04% (93.06%–101.19%), 98.45% (93.27%–103.91%) and 98.22% (93.15%–103.56%), respectively. The adjusted GMRs for essential pharmacokinetic (PK) parameters all met the requirements for bioequivalence, with values within the acceptable range of 80%–125%. In addition, the two drugs showed comparable results for the other PK parameters. These results indicate that the two drugs were bioequivalent. Furthermore, both drugs showed well safety. Conclusion: The research results proved that the PK and safety profiles of sunitinib in healthy Chinese subjects were comparable to those of Sutent ® . These results advocate the clinical application of generic sunitinib as a potential alternative to original product Sutent ® in the treatment of certain medical conditions.